0
0
Home » Pharmaceuticals

Chronic Myeloid Leukemia: Epidemiology Forecast to 2030

In the eight major markets (8MM), the diagnosed incident cases of CML are expected to increase from 15,515 cases in 2020, at an Annual Growth Rate (AGR) of more than 1%. In 2030, the US will have the highest number of diagnosed incident cases of CML in the 8MM, whereas Canada will have the fewest diagnosed incident cases. In the 8MM, the 20-year diagnosed prevalent cases of CML are expected to increase from 142,404 cases in 2020 at an AGR of more than 1.5%. GlobalData epidemiologists attribute the increase in the diagnosed incident cases and 20-year diagnosed prevalent cases of CML to population dynamics, as well as changes in the diagnosed incidence and survival rates in each market.

The diagnosed incidence of CML in men in the 8MM will increase minimally during 2010-2030. In 2020, Canada had the highest diagnosed incidence of CML in men with 2.67 cases per 100,000 population, followed by the US with 2.65 cases per 100,000 population and Japan with 2.28 cases per 100,000 population. In 2020, the UK had the lowest diagnosed incidence of CML in men with 1.39 cases per 100,000 population. The diagnosed incidence of CML in women in the 8MM will increase minimally during 2010-2030 similar to that observed for the incidence trends in men. In 2020, the US had the highest diagnosed incidence of CML in women, followed by Canada and Spain. In 2020, France had the lowest diagnosed incidence of CML in women. This report provides an overview of the risk factors, comorbidities, and the global and historical trends for CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).

What are the diagnosed incident cases of CML by staging?

In 2020, for the 8MM combined, the chronic phase accounted for the majority of the diagnosed incident cases of CML, with more than 90%, followed by the accelerated phase. The blast phase accounted for the fewest number of diagnosed incident cases of CML in the 8MM. This distribution was observed in all the markets.

Diagnosed incident cases of CML by staging

Diagnosed incident cases of CML by staging

For more insights, download a free report sample

What are the diagnosed incident cases of CML by risk status?

In 2020, for the 8MM combined, low-risk accounted for the majority of the diagnosed incident cases of CML, followed by intermediate-risk. High-risk accounted for the fewest number of diagnosed incident cases of CML in the 8MM with more than 20% cases. This distribution was similar in all the markets, except Italy, where intermediate-risk cases were marginally higher than low-risk cases.

Diagnosed incident cases of CML by risk status

Diagnosed incident cases of CML by risk status

For more insights, download a free report sample

What are the diagnosed incident cases of CML in the 8MM?

The 8MM include the US, Canada, France, Germany, Italy, Spain, the UK, and Japan. In 2020, the US accounted for more than 45% of the diagnosed incident cases of CML among the 8MM, with 7,433 cases. There were 4,988 cases in the 5EU in 2020, of the diagnosed incident cases, while Japan had more than 12% cases and Canada had more than 5% cases. In the 8MM, the number of diagnosed incident cases of CML will grow by more than 10% over the forecast period at an Annual Growth Rate (AGR) of more than 1% by 2030. Of the 8MM, Canada is expected to have the highest AGR of more than 2% with the diagnosed incident cases increasing by 2030. Canada will have the lowest number of diagnosed incident cases of CML in 2030. Any change in the diagnosed incident cases of CML is attributable to changing population demographics and changing diagnosed incident rates based on trend analysis in the 8MM.

Diagnosed incident cases of CML in the 8MM, by country

Diagnosed incident cases of CML in the 8MM, by country

For more regional insights, download a free report sample

Market report scope

Key stages Chronic Phase, Accelerated Phase, and Blast Phase
Risk Status Low-Risk, Intermediate-Risk, and High Risk
Key Countries The US, France, Germany, Italy, Spain, UK, Japan, and Canada

Scope

This report provides an in-depth analysis of the following:

  • The Chronic Myeloid Leukemia (CML) Epidemiology Report and Model provide an overview of the risk factors and global trends of CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CML. The diagnosed incident cases are segmented by age (all ages), sex, staging (chronic phase, accelerated phase, and blast phase), risk status (low-risk, intermediate-risk, and high-risk), and T315I mutation. The report also provides a 10-year epidemiological forecast of the 20-year diagnosed prevalent cases of CML. The model associated with this report additionally provides diagnosed incident cases of CML segmented by blast phase-lymphoid and blast phase-myeloid leukemia, as well as five-, 10-, and 15-year diagnosed prevalent cases of CML.
  • The CML epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Chronic Myeloid Leukemia (CML) Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global CML market.
  • Quantify patient populations in the global CML market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CML therapeutics in each of the markets covered.
  • Understand the magnitude of the CML population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Chronic Myeloid Leukemia: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Diagnosed Incident Cases of CML

2.4.4 Diagnosed Incident Cases of CML by Staging

2.4.5 Diagnosed Incident Cases of CML by Risk Status

2.4.6 Diagnosed Incident Cases of CML by T315I Mutation

2.4.7 Five-, 10-, 15-, 20-Year Diagnosed Prevalent Cases of CML

2.5 Epidemiological Forecast for CML (2020–2030)

2.5.1 Diagnosed Incident Cases of CML

2.5.2 Age-Specific Diagnosed Incident Cases of CML

2.5.3 Sex-Specific Diagnosed Incident Cases of CML

2.5.4 Diagnosed Incident Cases of CML by Staging

2.5.5 Diagnosed Incident Cases of CML by Risk Status

2.5.6 Diagnosed Incident Cases of CML by T315I Mutation

2.5.7 20-Year Diagnosed Prevalent Cases of CML

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with CML

List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of CML, Both Sexes, N, All Ages, 2020 and 2030

Figure 2: 8MM, 20-Year Diagnosed Prevalent Cases of CML, Both Sexes, N, All Ages, 2020 and 2030

Figure 3: 8MM, Diagnosed Incidence of CML, Men, Cases Per 100,000 Population, All Ages, 2010–2030

Figure 4: 8MM, Diagnosed Incidence of CML, Women, Cases Per 100,000 Population, All Ages, 2010–2030

Figure 5: 8MM, Sources Used to Forecast Diagnosed Incident Cases of CML (ICD-10 = C92.1)

Figure 6: 8MM, Sources Used to Forecast the Five-, 10-, 15-, and 20-Year Diagnosed Prevalent Cases of CML (ICD-10 = C92.1)

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by Staging

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by Risk Status

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by T315I Mutation

Figure 10: 8MM, Diagnosed Incident Cases of CML, N, Both Sexes, All Ages, 2020

Figure 11: 8MM, Diagnosed Incident Cases of CML by Age, N, All Ages, 2020

Figure 12: 8MM, Diagnosed Incident Cases of CML by Sex, N, All Ages, 2020

Figure 13: 8MM, Diagnosed Prevalent Cases of CML by Staging, N, All Ages, 2020

Figure 14: 8MM, Diagnosed Incident Cases of CML by Risk Status, N, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases of CML by T315I Mutation, N, Both Sexes, All Ages, 2020

Figure 16: 8MM, 20-Year Diagnosed Prevalent Cases of CML, N, Both Sexes, All Ages, 2020

Frequently Asked Questions

In the eight major markets (8MM), there were 15,515 diagnosed incident cases of CML in 2020.

In the eight major markets (8MM), the diagnosed incident cases of CML are expected to increase at an Annual Growth Rate (AGR) of more than 1% during 2021-2030.

In 2020, the US accounted for more than 45% of the diagnosed incident cases of CML among the 8MM.

In 2020, for the 8MM combined, low-risk accounted for the majority of the diagnosed incident cases of CML, followed by intermediate-risk and high-risk.

 

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports